Classes
(Oral and Non Insulin Agents)

Coverage Color Legend

Provinces (Two-Letter Abbreviation)

= No information

= Product not available

= Covered

= Possible Private Coverage

= Conditional public Coverage
(Touch box for more details)


BIGUANIDES
Oral medications

Metformin
Glucophage®
500 mg - 850 mg
OD to TID
Maximum daily dose: 2550 mg
Coverage


- Characteristics and clinical considerations

Metformin ER
Glumetza®
500 mg - 1000 mg
OD
Maximum daily dose: 2000 mg
Coverage


- Characteristics and clinical considerations

ALPHA-GLUCOSIDASE INHIBITOR
Oral medications

Acarbose
GlucobayTM
50 mg - 100 mg
OD to TID
Maximum daily dose: 300 mg
How to initiate
Coverage


- Characteristics and clinical considerations

DPP-4 INHIBITORS
Oral medications
Treatment of Type 2 Diabetes in Adults.

1. Sitagliptin Januvia®
2. Saxagliptin Onglyza®
3. Linagliptin Trajenta®
4. Alogliptin Nesina®

- Legend:

: Official indication according to Health Canada

- 1 2 3 4
Mono
Metformin
Sulfonylurea
Met + Sulfo
Insulin

Alogliptin
Nesina®
6.25 mg - 12.5 mg - 25 mg
OD
Coverage

QC
- Characteristics and clinical considerations

Alogliptin and Metformin
KazanoTM
12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Coverage

QC
- Characteristics and clinical considerations

Linagliptin
Trajenta®
5 mg
OD
Coverage
AB BC MB NB NL
NS PE QC SK
- Characteristics and clinical considerations

Linagliptin and Metformin
JentaduetoTM
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Coverage
AB BC MB NB NL
NS PE QC SK
- Characteristics and clinical considerations

Saxagliptin
Onglyza®
2.5 mg - 5 mg
OD
Coverage
AB BC MB NB NL
NS PE QC SK
- Characteristics and clinical considerations

Saxagliptin and Metformin
Komboglyze®
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Coverage
AB BC MB NB NL
NS PE QC SK
- Characteristics and clinical considerations

Sitagliptin
Januvia®
25 mg - 50 mg - 100 mg
OD
Coverage
AB MB NB NL
NS PE QC SK
- Characteristics and clinical considerations

Sitagliptin and Metformin
Janumet®
50 mg/500 mg - 50 mg/850 mg - 50 mg/1000 mg
BID
Coverage
AB MB NB NL
NS PE QC SK
- Characteristics and clinical considerations

Sitagliptin and Metformin ER
Janumet® XR
50 mg/500 mg - 50 mg/1000 mg - 100 mg/1000 mg
OD
Coverage
AB MB NB NL
PE QC SK
- Characteristics and clinical considerations

SGLT2 INHIBITORS
Oral medications
Treatment of Type 2 Diabetes in Adults.

1. Canagliflozin Invokana®
2. Dapagliflozin Forxiga®
3. Empagliflozin Jardiance®

  • Dapagliflozin is not indicated with Pioglitazone because of a possible link with bladder cancer
  • Sitagliptin is indicated for use with Dapagliflozin and Canagliflozin
- Legend:

: Official indication according to Health Canada.

*Please refer to Health Canada for most recent updates.

- 1 2 3
Mono
Metformin
Sulfonylurea
Met + Sulfo
Met+TZD(pio)
Insulin
DPP4. inh

Canaglifozin
Invokana®
100 mg - 300 mg
OD
Coverage
AB MB NB NL
NS PE QC SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Canaglifozin and Metformin
Invokamet®
50 mg/500 mg - 50 mg/1000 mg - 150 mg/500 mg - 150 mg/1000 mg
BID
Coverage
MB
PE
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Dapagliflozin
Forxiga®
5 mg - 10 mg
OD
Coverage
AB MB NB NL
NS PE QC SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Dapagliflozin and Metformin
Xigduo®
5 mg/850 mg - 5 mg/1000 mg
BID
Coverage
AB MB NB NL
NS PE QC SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Empagliflozin
Jardiance®
10 mg - 25 mg
OD
Coverage
AB BC MB NB NL
NS PE QC SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Empagliflozin and Linagliptin
Glyxambi®
10 mg/5 mg - 25 mg/5 mg
OD
Coverage


- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Empagliflozin and Metformin
SynjardyTM
5 mg/500 mg - 5/850 mg - 5 mg/1000 mg - 12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Coverage
BC NB
NS PE QC SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

INSULIN SECRETAGOGUES
Oral medications

Gliclazide
Diamicron®
80 mg
OD to BID
Maximum daily dose: 320 mg
Coverage
BC

- Characteristics and clinical considerations

Gliclazide Modified Release
Diamicron®MR
30 mg - 60 mg
OD
Maximum daily dose: 120 mg
Coverage
BC

- Characteristics and clinical considerations

Glimepiride
Amaryl®
1 mg - 2 mg - 4 mg
OD to BID
Maximum daily dose: 8 mg
Coverage
MB
ON QC
- Characteristics and clinical considerations

Glyburide
Diabeta®
2.5 mg - 5 mg
OD to BID
Maximum daily dose: 20 mg
Coverage


- Characteristics and clinical considerations

Repaglinide
GlucoNorm®
0.5 mg - 1 mg - 2 mg
OD to TID AC
Maximum daily dose: 16 mg
Coverage
MB NL
ON SK
- Characteristics and clinical considerations

THIAZOLIDINEDIONES (TZD)
Oral medications

Pioglitazone
Actos®
15 mg - 30 mg - 45 mg
OD
Coverage
AB BC MB NB NL
NS ON PE QC SK
- Characteristics and clinical considerations

Rosiglitazone
Avandia®
2 mg - 4 mg - 8 mg
OD
Coverage
AB
ON QC SK
- Characteristics and clinical considerations

GLP-1R AGONISTS
Injectable medications s/c
Treatment of Type 2 Diabetes in Adults.

1. Liraglutide Victoza®
2. Exenatide Byetta®
3. Exenatide (1QW) Bydureon®
4. Dulaglutide Trulicity®
5. Lixisenatide AdlyxineTM
6. Semaglutide Ozempic®

- Legend:

: Official indication according to Health Canada

- Please refer to the updated version of the product monograph at all times.
- 1 2 3 4 5
Mono
Metformin
Sulfonylurea
Met + Sulfo
Insulin

Dulaglutide
Trulicity®
0.75 mg - 1.5 mg
Once-Weekly
Stability at room temperature : 14 days
Coverage

QC
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Exenatide
Byetta®
5 µg - 10 µg
BID (60 min AC)
Stability at room temperature : 30 days
Coverage


- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Exenatide Sustained Release
Bydureon®
2 mg
Once-Weekly
Stability at room temperature : 4 weeks
Coverage


- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Liraglutide
Victoza®
0.6 mg - 1.2 mg - 1.8 mg
OD
Stability at room temperature : 30 days
Coverage

QC
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Lixisenatide
AdlyxineTM
10 ug/dose (0.05 mg/ml)
20 ug/dose (0.1 mg/ml)
OD
Stability at room temperature : 14 days
Not covered / Private coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Semaglutide (s/c)
Ozempic®
0.25 mg - 0.5 mg - 1 mg
Once-Weekly
Stability at room temperature : 8 weeks
Coverage
AB NB NL
NS PE QC SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Semaglutide (oral)
Rybelsus®
3 mg - 7 mg - 14 mg
OD
Private coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Glargine U100 (100 units/ml) / Lixisenatide (33 mcg/ml)
SoliquaTM
Maximum recommended daily dose is 60 units:
Glargine U100 60 units / Lixisenatide 20 mcg
Therapy Initiation and Titration
Coverage


- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Degludec (100 units/ml) / Liraglutide (3.6 mg/ml)
Xultophy®
Maximum recommended daily dose is 50 units:
Degludec 50 units / Liraglutide 1.8 mg
Therapy Initiation and Titration
Coverage


- Cardio-renal protection clinical data
- Characteristics and clinical considerations